"GLP-1" has become the shorthand for the entire modern weight-loss industry — but it is not the name of a medicine. It is the name of a hormone, and a whole family of medicines that act on it. Some of those medicines are licensed for weight management in Ireland. Some are licensed only for type 2 diabetes. And some of the substances being sold online as "GLP-1s" are not licensed anywhere. Here is the map, checked on 8 October 2026.
GLP-1 in Ireland: the quick answer
Quick answer (checked 8 October 2026): four GLP-1 medicines are licensed for weight management in Ireland — Wegovy (semaglutide injection), Mounjaro (tirzepatide injection), Saxenda (liraglutide injection) and, since 15 July 2026, the Wegovy pill (oral semaglutide). Ozempic and Rybelsus contain GLP-1 ingredients but are licensed only for type 2 diabetes. Retatrutide and orforglipron (Foundayo) are not licensed in the EU at all, and no GLP-1 medicine in Ireland can legally be supplied without a doctor's prescription.
Try the Slimbr weight loss plan
First month service fee just €49. If the doctor decides it's not suitable for you, your doctor consultation is free.
What "GLP-1" actually means
GLP-1 stands for glucagon-like peptide-1, a hormone your body releases naturally after eating. Among other things, it slows how quickly the stomach empties, signals fullness to the brain, and helps the body release insulin when blood sugar rises. It is something you already have — the medicines simply act on that system.
The medicines built around it are called GLP-1 receptor agonists: molecules that behave like the hormone and switch on the same receptors. If you want the full mechanism — what the hormone does, how the injections were derived from it, and what the studies measured — we cover that in how GLP-1 injections actually work.
A footnote you will rarely see on social media: Mounjaro's active ingredient, tirzepatide, is strictly speaking a dual agonist — it acts on GIP receptors as well as GLP-1 receptors. It is universally grouped with the GLP-1 family, and we do the same in this article, but the label is a simplification, not a precise description.
The GLP-1 medicines licensed for weight management in Ireland
A medicine's licence is the formal statement — approved at EU level by the European Medicines Agency (EMA) — of the condition it may be used to treat, in which patients, and at which doses. "Licensed for weight management" means the medicine was studied in people with obesity and authorised specifically for that use. As of October 2026, four products hold that licence in Ireland:
| Medicine | Active ingredient | Form | Licensed for |
|---|---|---|---|
| Wegovy | Semaglutide | Weekly injection | Weight management |
| Mounjaro | Tirzepatide | Weekly injection | Weight management and type 2 diabetes |
| Saxenda | Liraglutide | Daily injection | Weight management |
| Wegovy pill | Semaglutide (oral) | Daily tablet | Weight management (EU approval 15 July 2026) |
All four share the same licence shape: they are for adults with a BMI of 30 or above (obesity), or a BMI of 27 to under 30 (overweight) with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity (paediatric indications exist for some of these medicines but are outside this article’s scope). Meeting those thresholds makes you eligible for an assessment — it does not entitle you to a prescription. What each one is, briefly:
- Wegovy (semaglutide injection) — authorised EU-wide in January 2022 and available in Irish pharmacies since 2025. The once-weekly injection most people mean when they say "the weight-loss jab". Its maintenance dose is 2.4 mg weekly, with a 7.2 mg option for some adults. We compare it dose by dose with Ozempic in Ozempic vs Wegovy in Ireland.
- Mounjaro (tirzepatide injection) — the other once-weekly injection, licensed both for weight management and for type 2 diabetes. Tirzepatide is the ingredient behind much of the current research attention; what its EU licence actually says is explained in tirzepatide in Ireland: the licence in plain English.
- Saxenda (liraglutide injection) — the longest-established of the three injections and the only weight-management GLP-1 reimbursed on the community drug schemes, in a narrow group of patients under an HSE managed access protocol. It is a daily, not weekly, injection; we cover its side-effect profile in Saxenda in Ireland: side effects and comparisons.
- The Wegovy pill (oral semaglutide) — approved across the EU on 15 July 2026, with Irish availability still rolling out — ask your pharmacist. Same ingredient as the Wegovy injection, as a once-daily 25 mg tablet. We cover what it costs and how the routine differs in the Wegovy pill in Ireland.
GLP-1s licensed only for type 2 diabetes: Ozempic and Rybelsus
Two well-known names belong on a different list. Ozempic (semaglutide injection) and Rybelsus (oral semaglutide) are licensed in Ireland for type 2 diabetes, not for weight loss. That is not a technicality: their product information, studied doses and patient groups are all diabetes-specific.
The confusion is understandable — Ozempic contains exactly the same ingredient as Wegovy, and it became shorthand for weight-loss injections through years of social-media coverage. But "the same ingredient" and "the same licensed medicine" are different things, and prescribers work to the licence. Whether a doctor ever prescribes outside a licence for a specific patient is a case-by-case medical decision — not something an article, an ad or an influencer can promise. The full breakdown is in our Ozempic vs Wegovy comparison.
Not licensed in Ireland: retatrutide, orforglipron (Foundayo) and "compounded" GLP-1s
A third group gets sold on hope. It should not.
- Retatrutide — a triple-hormone agonist still in clinical trials. It has no marketing authorisation anywhere in the world, including Ireland. What is actually known about it — and what is still assumption — is covered in retatrutide in Ireland: the evidence so far.
- Orforglipron (brand name Foundayo) — an oral GLP-1 from Eli Lilly. It was approved in the United States in April 2026 and in the UK in August 2026, but its EU application is still under review, with decisions generally estimated in 2027. It is not licensed or available in Ireland yet; the status is tracked in Foundayo (orforglipron): the weight-loss pill and Ireland.
- Compounded and counterfeit "GLP-1s" — unlicensed semaglutide sold through websites and social media, sometimes in cosmetic packaging, sometimes as falsified copies of real brands. The HPRA has repeatedly warned about these products after investigations found unsafe supply chains and seized significant quantities of falsified weight-loss pens. No GLP-1 medicine can legally be supplied in Ireland without a prescription from a doctor registered here. We go through the risks — and the questions to ask any provider — in buying GLP-1s online without a prescription: the risks.
The pattern to hold on to: the licensed list is short and boring, and that is the point. Everything on it has been assessed by a regulator, prescribed by a doctor and dispensed by a pharmacy. Everything off it is either still in trials, still in review, or outside the law entirely.
Try the Slimbr weight loss plan: first month service fee just €49 →
Did you know you can claim up to 75% back on your health insurance?
See how the claim works →How you legally get a GLP-1 in Ireland
Every medicine in the licensed list above is prescription-only. The legal path is the same for all of them, and it has three steps:
- A medical assessment with a doctor registered in Ireland. They review your BMI, health history, current medicines and goals against the licence criteria — BMI 30+, or 27+ with a weight-related condition — and decide whether any prescription medicine is clinically appropriate. A genuine assessment can end in "no".
- A prescription for a specific medicine, at a starting dose, if one is suitable. GLP-1s are started low and increased on a schedule set in the product information, with follow-up rather than a one-off transaction.
- Dispensing through a pharmacy, against that prescription. If a service you are looking at skips step 1, it is not a shortcut — it is a different, illegal category of supply.
If you are wondering where the eligibility line sits for you specifically, we break down the criteria — BMI thresholds, the qualifying weight-related conditions, and the checks a doctor makes — in who qualifies for weight-loss injections in Ireland.
On cost and coverage: none of the newer GLP-1s are reimbursed for weight management on the medical card or Drugs Payment Scheme — Saxenda remains the only one covered, and only for a narrow patient group under an HSE managed access protocol. Privately, prices vary by medicine, dose and how the service is structured, so we keep live price comparisons on dedicated pages: Mounjaro prices in Ireland and the medical-card picture in Mounjaro and the HSE: medical card and DPS.
If you would rather have a doctor look at the whole picture than decode brand names and licences yourself, the starting point is a proper medical assessment.
See if the Slimbr plan is right for you: first month service fee just €49 →
Frequently asked questions
What does GLP-1 stand for?
Glucagon-like peptide-1 — a hormone released naturally after eating, involved in fullness, digestion and blood-sugar control. "GLP-1 medicines" are receptor agonists: molecules that act like this hormone. The hormone is already in your body; the medicines target the same system.
Is Ozempic a GLP-1?
Yes — Ozempic's semaglutide is a GLP-1 receptor agonist. But in Ireland Ozempic is licensed for type 2 diabetes, not weight management. The licensed semaglutide product for weight management is Wegovy (injection) or the Wegovy pill (tablet).
Which GLP-1s are licensed for weight loss in Ireland?
Four: Wegovy, Mounjaro, Saxenda and the Wegovy pill (oral semaglutide, EU-approved July 2026). All are prescription-only and licensed for adults with a BMI of 30 or above, or 27 to under 30 with a weight-related condition.
Can you get a GLP-1 without a prescription in Ireland?
No. Every GLP-1 medicine is prescription-only. Supply without a prescription is illegal, and the HPRA has warned about falsified and compounded products sold online. There is no legal "over the counter" version — the tablet included.
Are GLP-1 medicines covered by a medical card or the DPS?
For weight management, effectively no, with one narrow exception: Saxenda is reimbursed for a specific patient group under an HSE managed access protocol. The newer products are private. The current picture is covered in our HSE and medical card guide.
Is Mounjaro a GLP-1?
It is commonly described that way, and it is licensed for the same weight-management use. Strictly, tirzepatide is a dual GIP and GLP-1 receptor agonist — it acts on two hormone systems. For practical purposes (licence, access, monitoring) it sits alongside the GLP-1s.
What is the cheapest licensed GLP-1 in Ireland?
It depends on dose, medicine and how the prescribing service charges — some bundle the doctor and the medication, some separate them — so we keep this on live price-comparison pages rather than quoting one number here. The Mounjaro price comparison covers injections and the main Irish providers.
When will retatrutide or Foundayo be available in Ireland?
Retatrutide has no approval anywhere yet; it is still in trials. Foundayo (orforglipron) is approved in the US and UK but under EU review, with a decision generally estimated in 2027 — until then it is not licensed or available in Ireland. Anyone selling either today is selling an unlicensed product.
Further reading
- How GLP-1 injections work — the mechanism behind the whole class
- Who qualifies for weight-loss injections in Ireland — the eligibility criteria in detail
- Ozempic vs Wegovy in Ireland — same drug, different licence
- Every weight-loss medication licensed in Ireland — injections and tablets compared
- Mounjaro in Ireland: the complete guide — how the treatment works and follow-up
Sources: European Medicines Agency product information (SmPC) for Wegovy, Mounjaro, Saxenda and Ozempic (section 4.1 indications), read 8 October 2026. HPRA public statements on falsified semaglutide-type products. HSE managed access protocol for liraglutide (Saxenda). This article is general information, not medical advice; ask a doctor or pharmacist about your own situation.
